Chris Estes
A5025315719- Hepatitis C virus research
- Liver Disease Diagnosis and Treatment
- Hepatitis B Virus Studies
- Liver Disease and Transplantation
- Hepatitis Viruses Studies and Epidemiology
- Systemic Lupus Erythematosus Research
- Colorectal Cancer Screening and Detection
- Healthcare Systems and Reforms
- Colorectal Cancer Treatments and Studies
- Economic and Financial Impacts of Cancer
- Diet, Metabolism, and Disease
- Chronic Lymphocytic Leukemia Research
- Agriculture and Farm Safety
- Occupational Health and Performance
- Radiopharmaceutical Chemistry and Applications
- HIV/AIDS Impact and Responses
- Housing Market and Economics
- Gastric Cancer Management and Outcomes
- Urban, Neighborhood, and Segregation Studies
- Lymphoma Diagnosis and Treatment
- Advances in Oncology and Radiotherapy
- Cancer Genomics and Diagnostics
- Colorectal Cancer Surgical Treatments
- Health Systems, Economic Evaluations, Quality of Life
- Global Cancer Incidence and Screening
Exact Sciences (United States)
2023-2024
Center for Disease Analysis
2012-2023
Creative Research Enterprises (United States)
2016
Hospital Británico de Buenos Aires
2016
Centro de Educación Médica e Investigaciones Clínicas Norberto Quirno
2016
Hospital Universitario Austral
2016
National University of Rosario
2016
Hospital de Clínicas "José de San Martín"
2016
University of Buenos Aires
2016
Hospital Italiano de Buenos Aires
2016
Summary The disease burden of hepatitis C virus ( HCV ) is expected to increase as the infected population ages. A modelling approach was used estimate total number viremic infections, diagnosed, treated and new infections in 2013. In addition, model change progression mortality 2013–2030. Finally, expert panel consensus capture current treatment practices each country. Using today's paradigm, projected decline or remain flat all countries studied. However, same time period, individuals with...
Hepatitis C virus (HCV) infection is a leading cause of cirrhosis, hepatocellular carcinoma, and liver transplantation. A better understanding HCV disease progression the associated cost can help medical community manage develop treatment strategies in light emergence several potent anti-HCV therapies. system dynamic model with 36 cohorts was used to provide maximum flexibility improved forecasting. New infections incidence 16,020 (95% confidence interval, 13,510-19,510) estimated 2010....
•With only 10 years left to meet the WHO's hepatitis elimination targets, COVID-19 is impacting progress.•A 1-year delay in HCV programs could cause excess morbidity and mortality.•A 72,000 deaths from HCV.•Most would be lower middle income high-income groups. Background & AimsCoronavirus disease 2019 (COVID-19) has placed a significant strain on national healthcare systems at critical moment context of elimination. Mathematical models can used evaluate possible impact programmatic delays...
Summary The number of hepatitis C virus ( HCV ) infections is projected to decline while those with advanced liver disease will increase. A modeling approach was used forecast two treatment scenarios: (i) the impact increased efficacy keeping treated patients constant and (ii) increasing rate. This analysis suggests that successful diagnosis a small proportion can contribute significantly reduction burden in countries studied. largest ‐related morbidity mortality occurs when combined higher...
Morbidity and mortality attributable to chronic hepatitis C virus (HCV) infection are increasing in many countries as the infected population ages. Models were developed for 15 quantify characterize viremic population, well estimate number of new infections HCV related deaths from 2013 2030. Expert consensus was used determine current treatment levels outcomes each country. In most countries, prevalence has already peaked. every country studied, begins decline before 2030, when held...
Due to epidemic levels of obesity and type 2 diabetes mellitus (DM), nonalcoholic fatty liver disease (NAFLD) resulting steatohepatitis (NASH) will be driving factors in burden the coming years Saudi Arabia United Arab Emirates (UAE).Models were used estimate NAFLD NASH progression, primarily based on changes adult prevalence rates DM. The published estimates expert interviews build validate model projections.In both countries, increased through 2030 parallel projected increases By 2030,...
Summary The hepatitis C virus ( HCV ) epidemic was forecasted through 2030 for 15 countries in Europe, the Middle East and Asia, relative impact of two scenarios considered: increased treatment efficacy while holding annual number treated patients constant an patients. Increasing levels diagnosis treatment, combination with improved efficacy, were critical achieving substantial reductions disease burden. A 90% reduction total infections within years is feasible most studied, but it required...
Summary Chronic hepatitis C virus ( HCV ) infection is a leading cause of liver related morbidity and mortality. In many countries, there lack comprehensive epidemiological data that are crucial in implementing disease control measures as new treatment options become available. Published literature, unpublished expert consensus were used to determine key parameters, including prevalence, viremia, genotype the number patients diagnosed treated. this study 15 viremic prevalence ranged from...
The prevalence of hepatitis C virus (HCV) infection in Egypt is the highest world, yet total economic burden has not been quantified. Improved understanding costs and impact treatment strategies will provide for better allocation resources to reduce HCV disease burden.A modelling approach was used quantify current HCV-infected population, future progression associated Egypt.Direct healthcare were calculated from a nationally representative hospital disability adjusted life year (DALY)...
Chronic hepatitis C virus (HCV) infection is an important cause of advanced liver disease and liver-related deaths in Australia. Our aim was to describe the burden HCV consider treatment strategies reduce HCV-related morbidity mortality.Baseline model parameters were based upon literature review expert consensus with a focus on Australian data. Three scenarios anticipated introduction improved direct-acting antiviral regimens considered burden. Scenario 1 evaluated impact increased efficacy...
Abstract Background and Aim Interferon‐free direct‐acting antiviral regimens for hepatitis C virus (HCV) infection have been recently available in Australia, beginning a new era clinical public health management of HCV infection. This study provided updated estimates the care cascade burden Australia as reliable platform assessing future impact interferon‐free therapies. Methods A modeling approach was applied to estimate number individuals living with chronic various liver disease stages....
Summary The total number, morbidity and mortality attributed to viraemic hepatitis C virus ( HCV ) infections change over time making it difficult compare reported estimates from different years. Models were developed for 15 countries quantify characterize the population forecast changes in infected corresponding disease burden 2014 2030. With exception of Iceland, Iran, Latvia Pakistan, number is expected decline 2030, but associated are increase all except Japan South Korea. In latter two...
Summary Subsidized direct‐acting antiviral (DAA) treatment recently became available to all adults living with chronic hepatitis C virus (HCV) in Australia. Based on rapid uptake (32 600 people initiated DAA 2016), we estimated the impact HCV epidemiology and mortality Australia determined if can meet WHO elimination targets by 2030. Using a mathematical model, simulated pessimistic, intermediate optimistic scenarios over 2016‐2030. We assumed testing rates were initially higher for advanced...